InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (5 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
5
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the detailed record of transactions filed by Hughes Steven George, Chief Medical Officer. Insider active across 2 companies, notably Avidity Biosciences, Inc.. In total, 14 filings have been logged. Breakdown: 0 buy · 5 sells. Total volume traded: €672k. History available since 6 January 2025. The latest transaction was filed on 20 April 2026 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Hughes Steven George
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations14 total
30,000 shares0Common StockSEC:0001193125-26-170963:0
115,857 sharesCommon StockSEC:0001193125-26-082277:0
2,017 shares@ US$72.4513.8% of flowCommon StockSEC:0001599901-26-000026:0
2,373 shares@ US$72.2316.3% of flowCommon StockSEC:0001599901-26-000009:0
2,209 shares@ US$10.160.0085% mcap50.0% of flowCommon StockSEC:0001599901-25-000200:0
2,208 shares@ US$10.164.1% of flowCommon StockSEC:0001599901-25-000190:0
2,208 shares@ US$40.5816.5% of flowCommon StockSEC:0001599901-25-000190:1
1,542 shares@ US$6.571.4% of flowCommon StockSEC:0001599901-25-000186:0
2,208 shares@ US$10.163.1% of flowCommon StockSEC:0001599901-25-000166:0
1,542 shares@ US$6.571.4% of flowCommon StockSEC:0001599901-25-000159:0
11,283 shares@ US$15.9626.0% of flowCommon StockSEC:0001599901-25-000150:0
9,578 shares@ US$31.059859.4% of flowCommon StockSEC:0001599901-25-000075:0
1,915 shares@ US$28.595511.5% of flowCommon StockSEC:0001599901-25-000031:0
25,000 shares0Common StockSEC:0001599901-25-000019:0
14 of 14 declarations
About Hughes Steven George
Steven George Hughes is the Chief Medical Officer at Avidity Biosciences, Inc. He oversees the company's medical and clinical initiatives, ensuring that the developed products meet safety and efficacy standards. His role is crucial for innovation and treatment development in the biotechnology field.
